CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis

Kenneth E Lipson, Carol Wong, Yuchin Teng, Suzanne Spong, Kenneth E Lipson, Carol Wong, Yuchin Teng, Suzanne Spong

Abstract

CTGF is a secreted matricellular protein with very complex biology. It has been shown to modulate many signaling pathways leading to cell adhesion and migration, angiogenesis, myofibroblast activation, and extracellular matrix deposition and remodeling, which together lead to tissue remodeling and fibrosis. It has been reported in the literature that inhibition of CTGF expression by siRNA prevents CCl4-induced liver fibrosis and can reverse fibrosis when administered after significant collagen deposition is observed. A monoclonal antibody to CTGF that is currently in clinical development (FG-3019) has demonstrated the ability to reverse vascular stiffening and improve cardiac function in a rat model of diabetic complications. FG-3019 has also exhibited activity in a murine radiation-induced pulmonary fibrosis model. When FG-3019 was administered to mice after a significant radiation-induced increase in lung density could be observed by CT imaging, the density of the lungs was observed to decrease over the period during which the antibody was administered and to remain stable after therapy had ceased. When considered together, these data indicate that inhibition of CTGF can prevent and reverse the process of fibrosis.

Figures

Figure 1
Figure 1
CTGF affects multiple signaling pathways and processes important in pathophysiology. CTGF interacts with a variety of molecules, including cytokines and growth factors, receptors and matrix proteins. These interactions alter signal transduction pathways, either positively or negatively, which results in changes in cellular responses.
Figure 2
Figure 2
CTGF is a central mediator of tissue remodeling and fibrosis. Many different stimuli can induce expression of CTGF, which then promotes formation of myofibroblasts by modulating differentiation of other cells, including epithelial cells (EMT, epithelial to mesenchymal transition), resident fibroblasts or recruited fibrocytes (bone-marrow-derived, circulating mesenchymal stem cells). CTGF also promotes activation of the myofibroblasts and stimulates extracellular matrix (ECM) deposition and tissue remodeling. Remodeling in the vasculature can produce local hypertension that induces the expression of more CTGF, resulting in a positive feedback loop. Other positive feedback loops result from cytokines whose expression may be stimulated by CTGF, that in turn induce the expression of CTGF.
Figure 3
Figure 3
CTGF is essential for persistent fibrosis. One day old neonatal mice were injected SC daily for 7 days with 800 ng TGFβ2 alone or with 400 ng CTGF. FG-3019 was also administered to one group that received CTGF. The injections were then stopped for 4 days and the mice were sacrificed to examine the deposition of ECM components and cellular invasion. Panel A: the experimental design. Panel B: A cross section of the skin, SC space and underlying muscle from representative mice is shown. The arrows point out fibrotic response to the various treatments.
Figure 4
Figure 4
CTGF knock-down with shRNA inhibits serum-dependent cell proliferation of cardiac fibroblasts. Primary cardiac fibroblasts (P) were infected with lentiviruses encoding 2 different CTGF shRNAs (h2 and h5 from OpenBiosystems) or with a lentivirus generated from an empty vector (V) as control. Panel A: CTGF protein expression was measured by ELISA in culture supernatants. Panel B: 96 hrs after infection, cells were re-plated in quadruplicate wells of a 96-well plate in medium containing serum and defined growth supplements and incubated for up to 10 days. Cell proliferation was measured by Cyquant Fluorescense Intensity at the indicated timepoints. Panel C: Parallel cultures of cells were stained with crystal violet at day 10 and doubling time (DT) was determined by linear regression analysis on the data shown in B. * p < 0.001 vs. vector by ANOVA.
Figure 5
Figure 5
CTGF knock-down with shRNA inhibits TGFb-dependent cell proliferation of cardiac fibroblasts. Primary cardiac fibroblasts (P) were infected with lentiviruses encoding CTGF shRNAs (h2 or h5) or with a lentivirus expressing a scrambled shRNA as control. Cells were serum starved for 24 hrs and replated in medium containing growth supplements and the indicated concentrations of TGFb (TGFb). Panel A: CTGF protein expression was measured after 7 days. Panel B: Cell proliferation was measured by Cyquant at the indicated timepoints.

References

    1. De Winter P, Leoni P, Abraham D. Connective tissue growth factor: Structure-function relationships of a mosaic, multifunctional protein. Growth Factors. 2008;26:80–91. doi: 10.1080/08977190802025602.
    1. Holbourn KP, Acharya KR, Perbal B. The CCN family of proteins: structure-function relationships. Trends Biochem Sci. 2008;33:461–473. doi: 10.1016/j.tibs.2008.07.006.
    1. Jaffa AA, Usinger WR, McHenry MB, Jaffa MA, Lipstiz SR, Lackland D. et al.Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J Clin Endocrinol Metab. 2008;93:1893–1900. doi: 10.1210/jc.2007-2544.
    1. Nguyen TQ, Tarnow L, Andersen S, Hovind P, Parving HH, Goldschmeding R. et al.Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2006;29:83–88. doi: 10.2337/diacare.29.01.06.dc05-1670.
    1. Gressner AM, Yagmur E, Lahme B, Gressner O, Stanzel S. Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis. Clin Chem. 2006;52:1815–1817. doi: 10.1373/clinchem.2006.070466.
    1. Kovalenko E, Tacke F, Gressner OA, Zimmermann HW, Lahme B, Janetzko A. et al.Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. J Viral Hepat. 2009;16:612–620. doi: 10.1111/j.1365-2893.2009.01110.x.
    1. Bradham DM, Igarashi A, Potter RL, Grotendorst GR. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol. 1991;114:1285–1294. doi: 10.1083/jcb.114.6.1285.
    1. Bornstein P, Sage E. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol. 2002;14:608–616. doi: 10.1016/S0955-0674(02)00361-7.
    1. Leask A, Abraham DJ. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci. 2006;119:4803–4810. doi: 10.1242/jcs.03270.
    1. Shi-wen X, Leask A, Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev. 2008;19:133–144. doi: 10.1016/j.cytogfr.2008.01.002.
    1. Chen CC, Lau LF. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol. 2009;41:771–783. doi: 10.1016/j.biocel.2008.07.025.
    1. Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol. 2002;4:599–604.
    1. Inoki I, Shiomi T, Hashimoto G, Enomoto H, Nakamura H, Makino K. et al.Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 2002;16:219–221.
    1. Nishida T, Kubota S, Fukunaga T, Kondo S, Yosimichi G, Nakanishi T. et al.CTGF/Hcs24, hypertrophic chondrocyte-specific gene product, interacts with perlecan in regulating the proliferation and differentiation of chondrocytes. J Cell Physiol. 2003;196:265–275. doi: 10.1002/jcp.10277.
    1. Chen Y, Abraham DJ, Shi-wen X, Pearson JD, Black CM, Lyons KM. et al.CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol Biol Cell. 2004;15:5635–5646. doi: 10.1091/mbc.E04-06-0490.
    1. Babic AM, Chen CC, Lau LF. Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol. 1999;19:2958–2966.
    1. Segarini PR, Nesbitt JE, Li D, Hays LG, Yates JR III, Carmichael DF. The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor is a receptor for connective tissue growth factor. J Biol Chem. 2001;276:40659–40667. doi: 10.1074/jbc.M105180200.
    1. Wahab NA, Weston BS, Mason RM. Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor TrkA. J Am Soc Nephrol. 2005;16:340–351. doi: 10.1681/ASN.2003100905.
    1. Wahab NA, Brinkman H, Mason RM. Uptake and intracellular transport of the connective tissue growth factor: a potential mode of action. Biochem J. 2001;359:89–97. doi: 10.1042/0264-6021:3590089.
    1. Oliver N, Sternlicht M, Gerritsen K, Goldschmeding R. Could aging human skin use a connective tissue growth factor boost to increase collagen content? J Invest Dermatol. 2010;130:338–341. doi: 10.1038/jid.2009.331.
    1. Gore-Hyer E, Shegogue D, Markiewicz M, Lo S, Hazen-Martin D, Greene EL. et al.TGF-beta and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physiol Renal Physiol. 2002;283:F707–F716.
    1. Paradis V, Dargere D, Bonvoust F, Vidaud M, Segarini P, Bedossa P. Effects and regulation of connective tissue growth factor on hepatic stellate cells. Lab Invest. 2002;82:767–774.
    1. Grotendorst GR, Rahmanie H, Duncan MR. Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J. 2004;18:469–479. doi: 10.1096/fj.03-0699com.
    1. Lee CH, Shah B, Moioli EK, Mao JJ. CTGF directs fibroblast differentiation from human mesenchymal stem/stromal cells and defines connective tissue healing in a rodent injury model. J Clin Invest. 2010;120:3340–3349. doi: 10.1172/JCI43230.
    1. Hishikawa K, Oemar BS, Nakaki T. Static pressure regulates connective tissue growth factor expression in human mesangial cells. J Biol Chem. 2001;276:16797–16803. doi: 10.1074/jbc.M010722200.
    1. de Las HN, Ruiz-Ortega M, Miana M, Ruperez M, Sanz-Rosa D, Aragoncillo P. et al.Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats. J Hypertens. 2007;25:629–638. doi: 10.1097/HJH.0b013e3280112ce5.
    1. Chaqour B, Goppelt-Struebe M. Mechanical regulation of the Cyr61/CCN1 and CTGF/CCN2 proteins. FEBS J. 2006;273:3639–3649. doi: 10.1111/j.1742-4658.2006.05360.x.
    1. Yang H, Huang Y, Chen X, Liu J, Lu Y, Bu L. et al.The role of CTGF in the diabetic rat retina and its relationship with VEGF and TGF-beta, elucidated by treatment with CTGFsiRNA. Acta Ophthalmol. 2010;88:652–659. doi: 10.1111/j.1755-3768.2009.01641.x.
    1. Liu FY, Xiao L, Peng YM, Duan SB, Liu H, Liu YH. et al.Inhibition effect of small interfering RNA of connective tissue growth factor on the expression of vascular endothelial growth factor and connective tissue growth factor in cultured human peritoneal mesothelial cells. Chin Med J (Engl) 2007;120:231–236.
    1. Nguyen TQ, Roestenberg P, Van Nieuwenhoven FA, Bovenschen N, Li Z, Xu L. et al.CTGF inhibits BMP-7 signaling in diabetic nephropathy. J Am Soc Nephrol. 2008;19:2098–2107. doi: 10.1681/ASN.2007111261.
    1. Wahab NA, Mason RM. A critical look at growth factors and epithelial-to-mesenchymal transition in the adult kidney. Interrelationships between growth factors that regulate EMT in the adult kidney. Nephron Exp Nephrol. 2006;104:e129–e134. doi: 10.1159/000094963.
    1. Mitu G, Hirschberg R. Bone morphogenetic protein-7 (BMP7) in chronic kidney disease. Front Biosci. 2008;13:4726–4739.
    1. Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A. et al.Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. J Cell Physiol. 1999;181:153–159. doi: 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>;2-K.
    1. Paradis V, Dargere D, Vidaud M, De GA, Huet S, Martinez V. et al.Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology. 1999;30:968–976. doi: 10.1002/hep.510300425.
    1. Hsu YC, Chiu YT, Lee CY, Lin YL, Huang YT. Increases in fibrosis-related gene transcripts in livers of dimethylnitrosamine-intoxicated rats. J Biomed Sci. 2004;11:408–417. doi: 10.1007/BF02254446.
    1. Li G, Xie Q, Shi Y, Li D, Zhang M, Jiang S. et al.Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med. 2006;8:889–900. doi: 10.1002/jgm.894.
    1. Brigstock DR. Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo. J Cell Commun Signal. 2009;3:5–18. doi: 10.1007/s12079-009-0043-9.
    1. Langsetmo I, Jacob CT, Zhang W, Oliver N, Lin A, Coker G. et al.Anti-CTGF human antibody therapy with FG-3019 prevents and reverses diabetes-induced cardiovascular complications in streptozotocin (STZ) treated rats. Diabetes. 2006;55(Suppl 1):A122.
    1. Huber PE, Bickelhaupt S, Peschke P, Tietz A, Wirkner U, Lipson KE. Reversal Of Established Fibrosis By Treatment With The Anti-CTGF Monoclonal Antibody FG-3019 In A Murine Model Of Radiation-Induced Pulmonary Fibrosis. Am J Respir Crit Care Med. 2010;181:A1054.
    1. Plathow C, Li M, Gong P, Zieher H, Kiessling F, Peschke P. et al.Computed tomography monitoring of radiation-induced lung fibrosis in mice. Invest Radiol. 2004;39:600–609. doi: 10.1097/01.rli.0000138134.89050.a5.
    1. Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F. et al.Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med. 2005;201:925–935. doi: 10.1084/jem.20041393.
    1. Armstrong T, Packham G, Murphy LB, Bateman AC, Conti JA, Fine DR. et al.Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004;10:7427–7437. doi: 10.1158/1078-0432.CCR-03-0825.
    1. Wenger C, Ellenrieder V, Alber B, Lacher U, Menke A, Hameister H. et al.Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene. 1999;18:1073–1080. doi: 10.1038/sj.onc.1202395.
    1. Hartel M, di Mola FF, Gardini A, Zimmermann A, Di Sebastiano P, Guweidhi A. et al.Desmoplastic reaction influences pancreatic cancer growth behavior. World J Surg. 2004;28:818–825. doi: 10.1007/s00268-004-7147-4.
    1. Karger A, Fitzner B, Brock P, Sparmann G, Emmrich J, Liebe S. et al.Molecular insights into connective tissue growth factor action in rat pancreatic stellate cells. Cell Signal. 2008;20:1865–1872. doi: 10.1016/j.cellsig.2008.06.016.
    1. Dornhofer N, Spong S, Bennewith K, Salim A, Klaus S, Kambham N. et al.Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2006;66:5816–5827. doi: 10.1158/0008-5472.CAN-06-0081.
    1. Bennewith KL, Huang X, Ham CM, Graves EE, Erler JT, Kambham N. et al.The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res. 2009;69:775–784. doi: 10.1158/0008-5472.CAN-08-0987.
    1. Aikawa T, Gunn J, Spong SM, Klaus SJ, Korc M. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther. 2006;5:1108–1116. doi: 10.1158/1535-7163.MCT-05-0516.

Source: PubMed

3
Prenumerera